The situation in India is dire and all variants associated with a surge need attention. But this man is 88 years-old, diabetic, two prior heart surgeries, and still had only mild symptoms (mild fever was reported) and is hospitalized out of caution likely because he is former PM.https://twitter.com/GabrielScally/status/1384452978086596616 …
-
Show this thread
-
The surge in India looks terrifying and reports are horrific. The hospital system may collapse, and India needs immediate support in all ways we can. This is unchecked exponential growth. The potential variant contribution (increased transmissibility?) doesn't change the basics.pic.twitter.com/UehtCPAIMs
51 replies 372 retweets 866 likesShow this thread -
There is already encouraging reports about vaccine efficacy out of India—breakthroughs appearing to be extremely rare despite dominance of variants. But that doesn't lessen the reality and the severity of their crisis. Exponential, unchecked growth is a crisis. ht
@munna_jajbatipic.twitter.com/WfuFEt1V3E
8 replies 37 retweets 222 likesShow this thread -
Replying to @zeynep @munna_jajbati
I can't see any published data other than phase II data against b117 UK strain? We also need control data to interpret vaccine effectiveness which is missing in that table.
1 reply 0 retweets 2 likes -
Replying to @chrischirp @munna_jajbati
Covaxin had interim phase III data out for more than a month, and more were announced this morning.https://timesofindia.indiatimes.com/india/bharat-biotech-announces-phase-3-results-all-you-need-to-know/articleshow/81312912.cms …
1 reply 0 retweets 4 likes -
I mean, keep an eye on it for sure, but the results so far are not discouraging. Crucially, though, they are in a terrible, terrible spot. Don't have a good basis for conclusion but wouldn't be surprised by higher transmissibility, at least, for B.1.167.https://www.livemint.com/news/india/bharat-biotech-s-covaxin-found-100-effective-against-severe-covid-disease-in-phase-3-interim-analysis-11618997960204.html …
1 reply 1 retweet 4 likes -
Replying to @zeynep @munna_jajbati
they are definitely encouraging against prevalent variants pre March 2021 (inc B117)... say less about B1617 as far as I can tell. Is there a paper on the back of the press release? there wasn't a link in the release or article...
2 replies 0 retweets 0 likes
No paper that I know of yet, but today's announcement has to include later than pre-March, news release says more cases "due to surge." Hopefully more soon. Still the exponential growth they face is here, already. The reports are horrifying. https://www.bharatbiotech.com/images/press/covaxin-phase3-clinical-trials-interim-results.pdf …
-
-
Thanks. Twitter will use this to make your timeline better. UndoUndo
-
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.